Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Evusheld

Important Updates

December 8, 2021 - The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Learn More >>

View All


.

AstraZeneca received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the investigational long-acting antibody (mAb) combination therapy, EVUSHELD (tixagevimab co-packaged with cilgavimab). The EUA allows healthcare providers to administer EVUSHELD (AZD7442) for pre-exposure prophylaxis (PrEP) of symptomatic COVID-19, prior to exposure to the virus. The drug can provide protection for those not expected to mount an adequate immune response following vaccination, including those who are immunocompromised due to a medical condition or immunosuppressive medications, as well as those individuals for whom COVID-19 vaccination is not recommended. EVUSHELD (AZD7442) is a combination of two long-acting antibodies (tixagevimab and cilgavimab) and is administered by intramuscular (IM) injection.

In alignment with the terms of the EUA for EVUSHELD (AZD7442), the U.S. Department of Health and Human Services (HHS) is overseeing the allocation and distribution of this product.  Recurring allocations to state and territorial health departments are determined based on the total adult population within the jurisdiction (pro rata allocation). 

Related Resources


  • This page last reviewed: January 12, 2022